Answers are grounded in this paper and cite their sources.
Nanovaccines improve cytotoxicity and activation of immune response in cancer immunotherapy, suggesting potential for better treatment outcomes.
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsnano.5c15637 . Methods including materials and instruments, antibodies used during Western blotting and flow cytometry, cells and animals, release profile of metformin from Met-PC-NPS, determination of residual metformin in Met-PC-NPs, quantification of the proportion of Met-PC-NP-loaded Met-PC-EVs, characterization of Met-PC-EVs, detection of OVA antigen in Met-PC-EVs, cellular uptake assay, ELISA assay, cytotoxicity killing assay, antitumor efficacy in prophylactic or therapeutic tumor model and in combination with αPD1, cytotoxicity of oxaliplatin against B16F10-OVA cells, level of dsDNA in Met-EVs from B16F10-OVA cells treated with different concentrations of oxaliplatin, release profile of metformin from Met-PC-NPs or free Metformin, ROS detection in B16F10 cells after receiving various treatments, endocytosis of coumarin 6-labeled Met-NC-NPs or Met-PC-NPs by B16F10-OVA cells, hydrodynamic diameter and zeta-potential of different preparations, stability test of Met-PC-NPs in biological fluids, stability test of Met-PC-EVs in biological fluids, Western blotting analysis for ER marker calreticulin, flow cytometric analysis for the OVA detection in B16F10-EVs or Met-PC-EVs, TEM images of B-PC-NPs, B-PC-EVs, quantification of PLGA nanoparticle-loaded EVs in Met-PC-EVs, measurement of DiI-labeled preparation uptake by BMDCs, uptake of DiI-labeled Met-PC-EVs by BMDCs in the presence of various endocytic inhibitors, maturation study of BMDCs treated with PBS, Metformin, and Met-PC-EVs by flow cytometry, assessment of DiI-labeled preparation uptake by RAW264.7 cells, uptake of DiI-labeled Met-PC-EVs by RAW264.7 cells treated with different endocytic inhibitors, maturation study of RAW264.7 cells treated with PBS, Metformin, and Met-PC-EVs by flow cytometry, in vivo biodistribution of various formulations, serum cytokine levels in C57BL/6 mice following vaccination with various formulations, cytokine levels in the supernatant of splenocytes from C57BL/6 mice immunized with different preparations, in vitro T-cell cytotoxicity assay at varying effector-to-target ratios, Western blot analysis for the B16F10 tumor specific antigen Trp2 in Met-EVs and Met-PC-EVs, flow cytometric analysis and immunostaining of tumor infiltrating CD8 + T-cells, flow cytometric analysis of tumor infiltrating Tregs, quantification of TRP2-specific CD8 + T-cells in peripheral blood from different preparations immunized C57BL/6 mice, separate DAPI and TUNEL channels of apoptosis tumor cell staining, safety assessment of B-PC-EVs and Met-PC-EVs, gating strategy of the flow cytometry analysis, whole blot of Western blot analysis, and characterization of Met-NC-NPs and Met-PC-NPs ( PDF )
No takes yet. Share an insight, caveat, or question.
Gong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: